Image Source: Pixabay

TM Editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

Viatris Inc. (VTRS) was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specializes in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focuses on generic and specialty drugs.

By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra.

While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Three key data points gauge Viatris or any dividend-paying firm.

The key three are:

(1) Price

(2) Dividends

(3) Returns

Those three keys also best tell whether any company has made, is making, and will make money.

VTRS Price

Share price fell about 4% in the past year from $11.88 to $11.41, as of Thursday’s market close.

In the past 3 years, the company’s share price has ranged from $10.05 to $13.53. (Its all-time high of $76.68 was reached April 30, 2015.

The company may repeat its average two years of annual past performance and its price could grow by $1.53 next year to $12.95.

VTRS Dividend

Viatris has paid variable quarterly dividends from January 1989 to June 2007 and from June 2021 to December 2024. The company’s most recent Q dividend of $0.12 was declared on November 5th for shareholders of record prior to November 22nd and the payout was made on December 13th. A forward-looking annual dividend of .0.48 yields 4.20% per Thursday’s closing price.

VTRS Returns

Putting it all together, a $2.01 estimated gross gain per share shows up by adding VTRS’s annual $0.48 dividend to the estimated $1.53 annual price gain, totaling that $2.01 gross amount.

A little over $1000 buys 88 shares at Thursday’s $11.42 share price.

A $10 broker fee (if charged), collected half at purchase and half at sale, might take about $0.11 per share out of the $2.01 gross gain to give us a net gain of $1.90 X 88 shares = $167.20 for about a 16.6% estimated net gain on the year.

Furthermore, the $42.00 annual dividend income from $1k invested in VTRS is over 3.67 times greater than the single-share price. By these numbers, VTRS may be an ideal dividend dog.

Therefore, you may choose to pounce on Viatris Inc. as a 64-year-old quarterly dividend-paying pharmaceutical company with a 20-year dividend record.

The exact track of Viatris future price and dividend will entirely be determined by market action and company finances.

Remember the best way to track stock performance and dividend payments is through direct ownership of company shares.

More By This Author:

Current Report: Tsumura
Current Report: Sundrug Co Ltd
Current Report: Patterson Companies